210 related articles for article (PubMed ID: 24630742)
1. Impact of primary negative symptoms on functional outcomes in schizophrenia.
Fervaha G; Foussias G; Agid O; Remington G
Eur Psychiatry; 2014 Sep; 29(7):449-55. PubMed ID: 24630742
[TBL] [Abstract][Full Text] [Related]
2. Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures.
Fervaha G; Foussias G; Siddiqui I; Agid O; Remington G
Schizophr Res; 2014 Apr; 154(1-3):89-92. PubMed ID: 24630140
[TBL] [Abstract][Full Text] [Related]
3. Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study.
Fervaha G; Agid O; Takeuchi H; Foussias G; Remington G
Schizophr Res; 2013 Dec; 151(1-3):203-8. PubMed ID: 24183751
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
5. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data.
Rabinowitz J; Levine SZ; Garibaldi G; Bugarski-Kirola D; Berardo CG; Kapur S
Schizophr Res; 2012 May; 137(1-3):147-50. PubMed ID: 22316568
[TBL] [Abstract][Full Text] [Related]
6. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
[TBL] [Abstract][Full Text] [Related]
7. Effect of antipsychotic withdrawal on negative symptoms in schizophrenia.
Miller DD; Flaum M; Arndt S; Fleming F; Andreasen NC
Neuropsychopharmacology; 1994 Aug; 11(1):11-20. PubMed ID: 7945739
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
Grant PM; Huh GA; Perivoliotis D; Stolar NM; Beck AT
Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
[TBL] [Abstract][Full Text] [Related]
9. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
Schoemaker JH; Jansen WT; Schipper J; Szegedi A
J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
[TBL] [Abstract][Full Text] [Related]
10. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia.
Fervaha G; Foussias G; Agid O; Remington G
Acta Psychiatr Scand; 2014 Oct; 130(4):290-9. PubMed ID: 24850369
[TBL] [Abstract][Full Text] [Related]
11. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.
Alvarez E; Ciudad A; Olivares JM; Bousoño M; Gómez JC
J Clin Psychopharmacol; 2006 Jun; 26(3):238-49. PubMed ID: 16702888
[TBL] [Abstract][Full Text] [Related]
12. Recognizing primary vs secondary negative symptoms and apathy vs expression domains.
Kirkpatrick B
J Clin Psychiatry; 2014 Apr; 75(4):e09. PubMed ID: 24813410
[TBL] [Abstract][Full Text] [Related]
13. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
14. Relationship of cognition and psychopathology to functional impairment in schizophrenia.
Mohamed S; Rosenheck R; Swartz M; Stroup S; Lieberman JA; Keefe RS
Am J Psychiatry; 2008 Aug; 165(8):978-87. PubMed ID: 18450928
[TBL] [Abstract][Full Text] [Related]
15. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Tollefson GD; Sanger TM; Lu Y; Thieme ME
Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219
[TBL] [Abstract][Full Text] [Related]
16. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
Stauffer VL; Song G; Kinon BJ; Ascher-Svanum H; Chen L; Feldman PD; Conley RR
Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076
[TBL] [Abstract][Full Text] [Related]
17. [Negative symptoms in schizophrenia - overview and practical implications].
Klaus F; Dorsaz O; Kaiser S
Rev Med Suisse; 2018 Sep; 14(619):1660-1664. PubMed ID: 30230774
[TBL] [Abstract][Full Text] [Related]
18. Motivational deficits in early schizophrenia: prevalent, persistent, and key determinants of functional outcome.
Fervaha G; Foussias G; Agid O; Remington G
Schizophr Res; 2015 Aug; 166(1-3):9-16. PubMed ID: 25982811
[TBL] [Abstract][Full Text] [Related]
19. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
20. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study.
Fervaha G; Agid O; Takeuchi H; Foussias G; Remington G
Eur Neuropsychopharmacol; 2014 Jul; 24(7):1078-85. PubMed ID: 24726579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
